Objective To investigate the clinical effect of Argon -Helium cryoablation combined with targeted drug therapy in the treatment of stage Ⅲ-Ⅳ non small cell carcinoma ( NSCLC).Methods Made a retrospective analysis of stage Ⅲ-ⅣNSCLC patients in Xinhui affiliated Hospital of Southern Medical University from January 2012 to March 2015, the 37 cases were treated by Argon -Helium cryoablation combined with targeted drug ( observation group ) , and another 70 cases were randomly selected and given targeted drugs only ( control group ) .Curative effects in the near future , the survival rate of follow -up and adverse reactions of the two groups were compared between the groups .Results Curative effect in the near future: in the observation group, 8 cases (21.6%) reached complete remission (CR), 18 cases (48.6%) obtained partial remission (PR), 11 cases (29.7%) without changes, none progression (0%), and the response rate was 70.3%.In control group, one case got CR (1.4%), 38 cases got PR (54.3%), 22 cases of NC (31.4%), 9 cases PD (12.9%), the RR was 55.7%.Observation group got better effective rate than control group (P<0.05). Median survival time of observation group was 16 months, which was significantly longer than 12 months of control group (P<0.05).Mean survival time of observation group (18.7 ±11.9 months) was significantly longer than control group (13.4 ±6.9 months) (P<0.05).Observation group got higher incidence in erythra (51.4%vs. 2.9%), diarrhoea (45.9%vs.5.7%), metabolic and nutritional abnormalities (13.5% vs.1.4%).There was no significant difference between the groups in the incidence of hemoptysis , fever, pneumothorax and pleural effusion (P>0.05).Conclusions The therapy of Argon -Helium cryoablation combined with targeted drug therapy is safe and effective for stage Ⅲ-ⅣNSCLC.This therapy can improve the outcome of the disease .%目的：探讨氩氦刀冷冻消融术联合靶向药物治疗Ⅲ～Ⅳ期非小细胞肺癌（ NSCLC）的临床疗效。方法回顾性分析南方医科大学附属新会医院2012年1月至2015年3月采用氩氦刀联合靶向药物治疗的Ⅲ～Ⅳ期NSCLC患者37例（观察组），并随机选取同期采用单纯靶向药物治疗的III－IV期NSCLC患者70例作为对照（对照组），比较分析两组的近期疗效、随访生存率及不良反应情况。结果近期疗效：观察组完全缓解8例（21．6％），部分缓解18例（48．6％），无变化11例（29．7％），进展0例，有效率70．3％；对照组完全缓解1例（1．4％），部分缓解38例（54．3％），无变化22例（31．4％），进展9例（12．9％），有效率55．7％，观察组疗效优于对照组（P＜0．05）。生存率：观察组中位生存时间为16个月，对照组为12个月；观察组平均生存时间为（18．7±11．9）个月，对照组平均生存时间为（13．4±6．9）个月，（ P＜0．05）。观察组在皮疹发生率（51．4％vs．2．9％）、腹泻发生率（45．9％ vs．5．7％）、代谢及营养异常（13．5％vs．1．4％）发生率均显著高于对照组（P＜0．05），而在咯血、发热、气胸及胸腔积液发生率两组比较无显著性差异（P＞0．05）。结论氩氦刀冷冻消融术联合靶向药物治疗Ⅲ－Ⅳ期NSCLC安全、有效，可更好提升患者预后情况。
展开▼
